Patents by Inventor Christian F. Helvig

Christian F. Helvig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110052567
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders; related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Application
    Filed: April 2, 2009
    Publication date: March 3, 2011
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Publication number: 20100120728
    Abstract: The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof.
    Type: Application
    Filed: April 25, 2008
    Publication date: May 13, 2010
    Applicant: CYTOCHROMA INC.
    Inventors: P. Martin Petkovich, Christian F. Helvig, Samir P. Tabash
  • Publication number: 20090209501
    Abstract: The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.
    Type: Application
    Filed: June 21, 2007
    Publication date: August 20, 2009
    Applicants: Proventiv Therapeutics, LLC., Cyctochroma, Inc.
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messener, Martin P. Petkovich, Christian F. Helvig